These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Iwami K; Shimato S; Ohno M; Okada H; Nakahara N; Sato Y; Yoshida J; Suzuki S; Nishikawa H; Shiku H; Natsume A; Wakabayashi T Cytotherapy; 2012 Jul; 14(6):733-42. PubMed ID: 22424217 [TBL] [Abstract][Full Text] [Related]
6. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy. Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465 [TBL] [Abstract][Full Text] [Related]
8. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Okada H; Kalinski P; Ueda R; Hoji A; Kohanbash G; Donegan TE; Mintz AH; Engh JA; Bartlett DL; Brown CK; Zeh H; Holtzman MP; Reinhart TA; Whiteside TL; Butterfield LH; Hamilton RL; Potter DM; Pollack IF; Salazar AM; Lieberman FS J Clin Oncol; 2011 Jan; 29(3):330-6. PubMed ID: 21149657 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020 [TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790 [TBL] [Abstract][Full Text] [Related]
11. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205 [TBL] [Abstract][Full Text] [Related]
12. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Fenstermaker RA; Ciesielski MJ; Qiu J; Yang N; Frank CL; Lee KP; Mechtler LR; Belal A; Ahluwalia MS; Hutson AD Cancer Immunol Immunother; 2016 Nov; 65(11):1339-1352. PubMed ID: 27576783 [TBL] [Abstract][Full Text] [Related]
13. Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. Babatz J; Röllig C; Oelschlägel U; Zhao S; Ehninger G; Schmitz M; Bornhäuser M J Hematother Stem Cell Res; 2003 Oct; 12(5):515-23. PubMed ID: 14594508 [TBL] [Abstract][Full Text] [Related]
15. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients. Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734 [TBL] [Abstract][Full Text] [Related]
17. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471 [TBL] [Abstract][Full Text] [Related]
19. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Wen PY; Reardon DA; Armstrong TS; Phuphanich S; Aiken RD; Landolfi JC; Curry WT; Zhu JJ; Glantz M; Peereboom DM; Markert JM; LaRocca R; O'Rourke DM; Fink K; Kim L; Gruber M; Lesser GJ; Pan E; Kesari S; Muzikansky A; Pinilla C; Santos RG; Yu JS Clin Cancer Res; 2019 Oct; 25(19):5799-5807. PubMed ID: 31320597 [TBL] [Abstract][Full Text] [Related]
20. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats. Zhu X; Lu C; Xiao B; Qiao J; Sun Y J Neurooncol; 2005 Aug; 74(1):9-17. PubMed ID: 16078102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]